Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


27 agosto 2013

Harvard researchers create vascular endothelial cells

Vascular News

Harvard Stem Cell Institute (HSCI) scientists have successfully grown the cells that line the blood vessels—called vascular endothelial cells—from human induced pluripotent stem cells (iPSCs), revealing new details about how these cells function.

06 agosto 2013

Cook Medical distributing Zilver PTX drug-eluting stent in USA, Europe and Japan

Interventional News

Cook Medical is shipping its Zilver PTX drug-eluting peripheral stent to medical centres in the USA, Japan, Europe and other major markets again. The shipments follow a brief period of unavailability due to a voluntary recall by Cook related to an issue with the stent’s delivery catheter that has been resolved.

08 agosto 2013

Are bioabsorbable stents the ideal REMEDY?

Interventional News

Peter Goverde who presented the Belgian registry results at EuroPCR 2013 in Paris, France (21–24 May), said that stenting of the superficial femoral artery with the biodegradable Remedy stent was safe and feasible.

15 julio 2013

Covidien Initiates ILLUMENATE Trials for the Stellarex Peripheral Drug-Coated Balloon

Endovascular Today

Covidien (Mansfield, MA) has commenced enrollment in the ILLUMENATE Pivotal and ILLUMENATE PK (Pharmacokinetics) trials, which are components of the global ILLUMENATE clinical trial program. This program is a series of studies on the safety and effectiveness of Covidien’s Stellarex drug-coated angioplasty balloon for the treatment of patients with peripheral arterial disease (PAD).

29 julio 2013

Cre8 BTK polymer-free drug-eluting stent receives the CE mark

Interventional News

CID announced on 18 July 2013 the CE mark of its drug-eluting stent for the treatment of below-the-knee lesions: the Cre8 BTK device. According to CID, the Cre8 BTK polymer-free device embodies the most advanced drug-eluting stent technologies to treat peripheral vascular disease. “Its unique distinctive features—Abluminal Reservoir Technology, Amphilimus formulation and Bio Inducer Surface – make Cre8 the only very effective polymer-free drug-eluting stent available today,” the company claimed.

17 julio 2013

Hansen Medical and Philips reinforce collaboration in robotic systems for endovascular interventions

Interventional News

Hansen Medical, and Royal Philips have announced that they have reached an important milestone in their long-term collaboration by securing certified compatibility between Hansen Medical’s Magellan Robotic System and Philips’ Allura interventional X-ray systems. According to a company release, article 12 compatibility covers specific technical and service requirements, and means that the Magellan Robotic System is compatible with Philips’ Allura live image-guidance systems when used according to instructions.

16 septiembre 2013

Cook Medical s Zilver PTX Shows Favorable 4-Year Revascularization Rate

Endovascular Today

Cook Medical (Bloomington, IN) announced that 83.2% of patients with femoropopliteal lesions who were treated with the company’s Zilver PTX self-expanding paclitaxel-coated nitinol stent did not require revascularization at 4 years. This freedom from target lesion revascularization (TLR) rate compares favorably to the 69.4% freedom from TLR rate at 4 years in patients treated with percutaneous transluminal angioplasty (PTA) and a bare metal stent.

05 julio 2013

Phase III study demonstrates significantly fewer major bleeding events with apixaban

Vascular News

The phase III AMPLIFY results, published in New England Journal of Medicine and presented as a late-breaking trial at the Congress of the International Society on Thrombosis and Haemostasis (29 June–4 July 2013, Amsterdam, The Netherlands) showed that apixaban achieved its primary endpoint of noninferiority to the current standard of care.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.